Todd E. Golde on Biogen/Eisai Halt Phase 3 Aducanumab Trials

COMMENT Was this the right drug at the wrong time? Or another "wrong" drug? (See Golde et al., 2018).  This is a critical question for the field to answer. There is evidence that this antibody reduces the amyloid PET ligand signal in many trial ...

Todd E. Golde on A Little Amyloid, A Lot of Trouble?

COMMENT These are fascinating studies. They remind us there is a lot we do not know about the biology of AD. They reinforce that we need to solve the mystery of how Aβ talks to tau. They also show that kinetics matter. There has been some literature (e.g. Wogulis ...

Todd E. Golde on Field Loses Chad Dickey, 40, to Cancer

COMMENT Chad was a great friend and colleague. I first met him when I was a young faculty member at Mayo Clinic in Florida, and Chad was a postdoctoral fellow. He was later promoted to a research track assistant professor and I soon thereafter became his chair. ...

Todd E. Golde on Early Events in AD Mice as Targets for Therapy

COMMENT I think we in this field have to be careful with overinterpreting phenomena in our APP mouse models. Transgenic mouse models expressing AD-associated mutant forms of the amyloid-β precursor protein (APP), or both mutant APP and mutant presenilin-1 (PS1), ...

Current Filters

  • TYPE: Comment x
  • Commentator: Golde, Todd E x

Remove all filters

Filter By

  • All
  • Past 7 Days
  • Past 30 Days
  • Past 90 Days
  • Past 12 Months
  • Specific Dates
    1. From